{"id":"https://openalex.org/W4361812673","doi":"https://doi.org/10.1158/1078-0432.c.6532329.v1","title":"Data from Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant","display_name":"Data from Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361812673","doi":"https://doi.org/10.1158/1078-0432.c.6532329.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6532329.v1","doi":"https://doi.org/10.1158/1078-0432.c.6532329.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6532329.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6532329.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091245889","display_name":"Masakazu Toi","orcid":"https://orcid.org/0000-0003-1488-9958","observed_orcids":["https://orcid.org/0000-0003-1488-9958"]},"institutions":[{"id":"https://openalex.org/I22299242","display_name":"Kyoto University","ror":"https://ror.org/02kpeqv85","country_code":"JP","type":"education","lineage":["https://openalex.org/I22299242"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masakazu Toi","raw_affiliation_strings":["Kyoto University, Kyoto, Japan"],"raw_orcid":"https://orcid.org/0000-0003-1488-9958","affiliations":[{"raw_affiliation_string":"Kyoto University, Kyoto, Japan","institution_ids":["https://openalex.org/I22299242"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007579054","display_name":"Patrick Neven","orcid":"https://orcid.org/0000-0002-1434-9460","observed_orcids":["https://orcid.org/0000-0002-1434-9460"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Patrick Neven","raw_affiliation_strings":["Universitaire Ziekenhuizen Leuven -Campus Gasthuisberg, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universitaire Ziekenhuizen Leuven -Campus Gasthuisberg, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030577122","display_name":"Joohyuk Sohn","orcid":"https://orcid.org/0000-0002-2303-2764","observed_orcids":["https://orcid.org/0000-0002-2303-2764"]},"institutions":[{"id":"https://openalex.org/I4405258038","display_name":"Yonsei Cancer Hospital","ror":"https://ror.org/0005vby86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I193775966","https://openalex.org/I2799970807","https://openalex.org/I4210160791","https://openalex.org/I4405258038"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Joohyuk Sohn","raw_affiliation_strings":["Yonsei Cancer Center, Seoul, Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yonsei Cancer Center, Seoul, Korea","institution_ids":["https://openalex.org/I4405258038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013148496","display_name":"Eva\u2010Maria Grischke","orcid":"https://orcid.org/0000-0001-7413-5053","observed_orcids":["https://orcid.org/0000-0001-7413-5053"]},"institutions":[{"id":"https://openalex.org/I4210094118","display_name":"Universit\u00e4tsklinikum T\u00fcbingen","ror":"https://ror.org/00pjgxh97","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210094118"]},{"id":"https://openalex.org/I4210122374","display_name":"Universit\u00e4ts Frauenklinik","ror":"https://ror.org/02veq1j93","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210094118","https://openalex.org/I4210122374"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Eva-Maria Grischke","raw_affiliation_strings":["Universitatsklinikum Tubingen Frauenklinik, Tubingen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universitatsklinikum Tubingen Frauenklinik, Tubingen, Germany","institution_ids":["https://openalex.org/I4210094118","https://openalex.org/I4210122374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030451537","display_name":"Antonio Llombart\u2010Cussac","orcid":"https://orcid.org/0000-0003-4515-8293","observed_orcids":["https://orcid.org/0000-0003-4515-8293"]},"institutions":[{"id":"https://openalex.org/I4210119293","display_name":"Hospital Arnau de Vilanova","ror":"https://ror.org/02s7fkk92","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210119293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Antonio Llombart-Cussac","raw_affiliation_strings":["Hospital Arnau Vilanova, Valencia, Spain"],"raw_orcid":"https://orcid.org/0000-0003-4515-8293","affiliations":[{"raw_affiliation_string":"Hospital Arnau Vilanova, Valencia, Spain","institution_ids":["https://openalex.org/I4210119293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090789911","display_name":"Hatem Hussein Soliman","orcid":"https://orcid.org/0000-0001-6644-2264","observed_orcids":["https://orcid.org/0000-0001-6644-2264"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hatem Soliman","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, Florida"],"raw_orcid":"https://orcid.org/0000-0001-6644-2264","affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100752802","display_name":"Hong Wang","orcid":"https://orcid.org/0000-0002-8787-715X","observed_orcids":["https://orcid.org/0000-0002-8787-715X"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Wang","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":"https://orcid.org/0000-0002-8787-715X","affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021147423","display_name":"Sameera R. Wijayawardana","orcid":"https://orcid.org/0000-0002-5187-167X","observed_orcids":["https://orcid.org/0000-0002-5187-167X"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sameera Wijayawardana","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":"https://orcid.org/0000-0002-5187-167X","affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048549140","display_name":"Valerie Malyvanh Jansen","orcid":"https://orcid.org/0009-0002-5754-6111","observed_orcids":["https://orcid.org/0009-0002-5754-6111"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Valerie M. Jansen","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081153905","display_name":"Lacey M. Litchfield","orcid":"https://orcid.org/0009-0004-5232-9585","observed_orcids":["https://orcid.org/0009-0004-5232-9585"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lacey M. Litchfield","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066769011","display_name":"George W. Sledge","orcid":"https://orcid.org/0000-0003-0297-0775","observed_orcids":["https://orcid.org/0000-0003-0297-0775"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George W. Sledge","raw_affiliation_strings":["Stanford University, Stanford, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University, Stanford, California","institution_ids":["https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5069056507"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/esr1-mutations","display_name":"ESR1 mutations","score":1.0},{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.972000002861023},{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hr-her2-breast-cancer","display_name":"hormone receptor-positive HER2-negative breast cancer","score":0.9049999713897705},{"id":"https://openalex.org/keywords/endocrine-resistance","display_name":"endocrine therapy resistance","score":0.8820000290870667},{"id":"https://openalex.org/keywords/cdk4-6-inhibition","display_name":"CDK4/6 inhibition","score":0.8889999985694885},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8970000147819519},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9559999704360962},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7210000157356262},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.3190000057220459},{"id":"https://openalex.org/keywords/exploratory-analysis","display_name":"exploratory analysis","score":0.5230000019073486}],"concepts":[{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.9742603302001953},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5797401666641235},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5413920283317566},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.49943089485168457},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4743213355541229},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4578380584716797},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4085322916507721},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.3591558337211609},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3396470546722412},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.20065554976463318},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0634564459323883},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6532329.v1","doi":"https://doi.org/10.1158/1078-0432.c.6532329.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6532329.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6532329.v1","doi":"https://doi.org/10.1158/1078-0432.c.6532329.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6532329.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W2021145743","https://openalex.org/W2073367400","https://openalex.org/W2159427817","https://openalex.org/W2374277491","https://openalex.org/W2604928956","https://openalex.org/W2767035762","https://openalex.org/W2889646458","https://openalex.org/W2896846857","https://openalex.org/W2907884187","https://openalex.org/W3083789602","https://openalex.org/W3109453522","https://openalex.org/W3120684612","https://openalex.org/W3123151883"],"related_works":["https://openalex.org/W4210430911","https://openalex.org/W2955881909","https://openalex.org/W3082960402","https://openalex.org/W3166806042","https://openalex.org/W3031762863","https://openalex.org/W4225616440","https://openalex.org/W2898116555","https://openalex.org/W7035962836","https://openalex.org/W4399324796","https://openalex.org/W7129459287"],"abstract_inverted_index":{"AbstractPurpose:":[0],"PIK3CA":[1,64,131,155,243,256],"and":[2,24,72,119,123,146,184,214,266],"ESR1":[3,66,133,157,245,258],"mutations":[4,67,134],"have":[5],"been":[6,27],"implicated":[7],"in":[8,14,37,59,68,88,126,136,170,263,273,292],"resistance":[9,36],"to":[10,33,52,104,277],"endocrine":[11,35],"therapy":[12],"(ET)":[13],"HR+,":[15,92,295],"HER2\u2212":[16,93,296],"advanced":[17],"breast":[18,43],"cancer":[19],"(ABC).":[20],"Inhibition":[21],"of":[22,47,55,84,242,255],"CDK4":[23],"6":[25],"has":[26],"hypothesized":[28],"as":[29,198,200],"a":[30,77,269],"therapeutic":[31],"strategy":[32],"overcome":[34],"patients":[38,60,127],"with":[39,61,91,128,166,237,261,268,287,294],"PIK3CA-":[40,282],"or":[41,62,65,109,129,132,156,244,257,283],"ESR1-mutant":[42,215,284],"cancers.":[44],"The":[45],"objective":[46],"this":[48],"exploratory":[49],"analysis":[50],"was":[51,76,252],"assess":[53],"efficacy":[54],"abemaciclib":[56,85,106,238],"plus":[57,86,107,111,161,168,239,250,279],"fulvestrant":[58,87,108,162,169,240,251,280],"without":[63,130],"MONARCH":[69,74,142],"2.":[70],"Patients":[71,100],"Methods:":[73],"2":[75,143],"global,":[78],"randomized,":[79],"double-blind":[80],"phase":[81],"III":[82],"trial":[83],"669":[89],"women":[90,293],"ABC,":[94],"which":[95],"had":[96,299],"progressed":[97,300],"on":[98,301],"ET.":[99,302],"were":[101,150,232],"randomized":[102],"2:1":[103],"receive":[105],"placebo":[110,167,278],"fulvestrant.":[112],"Exploratory":[113],"analyses":[114],"assessed":[115],"progression-free":[116],"survival":[117,121],"(PFS)":[118],"overall":[120],"(OS),":[122],"other":[124],"endpoints,":[125,229],"detectable":[135],"baseline":[137],"ctDNA.":[138],"Results:":[139],"From":[140],"the":[141,288],"population,":[144],"219":[145],"248":[147],"patient":[148],"samples":[149],"successfully":[151],"analyzed":[152],"for":[153,281],"either":[154],"mutations,":[158],"respectively.":[159],"Abemaciclib":[160,249],"improved":[163,234],"PFS":[164,265,275],"compared":[165,286],"both":[171,201,264],"PIK3CA-wild-type":[172],"(median":[173,187,203,217],"16.9":[174],"months":[175,189,205,219],"vs.":[176,190,206,220],"12.3":[177],"months;":[178,192,208,222],"HR,":[179,193,209,223],"0.51;":[180],"95%":[181,195,211,225],"CI,":[182,196,212,226],"0.33\u20130.78)":[183],"PIK3CA-mutant":[185],"subgroups":[186,216],"17.1":[188],"5.7":[191],"0.53;":[194],"0.33\u20130.84),":[197],"well":[199],"ESR1-wild-type":[202],"15.3":[204],"11.2":[207],"0.44;":[210],"0.27\u20130.71)":[213],"20.7":[218],"13.1":[221],"0.54;":[224],"5.7\u201316.9).":[227],"Additional":[228],"including":[230],"OS,":[231,267],"also":[233],"following":[235],"treatment":[236],"regardless":[241,254],"mutation":[246,259],"status.":[247],"Conclusions:":[248],"effective":[253],"status,":[260],"benefit":[262],"numerically":[270],"greater":[271],"improvement":[272],"median":[274],"relative":[276],"tumors":[285],"respective":[289],"wild-type":[290],"subgroups,":[291],"ABC":[297],"that":[298]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2023-04-05T00:00:00"}